Thera-SAbDab

RUPLIZUMAB

>   Structural Summary
TherapeuticRuplizumab
TargetCD40LG
Heavy ChainQVQLVQSGAEVVKPGASVKLSCKASGYIFTSYYMYWVKQAPGQGLEWIGEINPSNGDTNFNEKFKSKATLTVDKSASTAYMELSSLRSEDTAVYYCTRSDGRNDMDSWGQGTLVTVSS
Light ChainDIVLTQSPATLSVSPGERATISCRASQRVSSSTYSYMHWYQQKPGQPPKLLIKYASNLESGVPARFSGSGSGTDFTLTISSVEPEDFATYYCQHSWEIPPTFGGGTKLEIK
100% seqID Fv Structure1i9r [Fvs: HL, KM, XY]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Discontinued
Recorded Developmental Technologyna
INN Year Proposed2000
INN Year Recommended2001
Companies InvolvedBiogen
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedAutoimmune disorders, Haemophilia A, Idiopathic thrombocytopenic purpura, Multiple sclerosis, Renal transplant rejection, Systemic lupus erythematosus
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]